https://www.selleckchem.com/pr....oducts/fenretinide.h
individualized cortical modulation for treating VD in MS patients. Results from this study will provide a better understanding of the brain control of neurogenic bladders and lay the foundation for a potential alternative therapy for VD in MS patients and other NLUTD in a larger neurogenic population in the future. This trial is registered at ClinicalTrials.Gov ( NCT03574610 , 2 July 2018.) and Houston Methodist Research Institute IRB (PRO00019329). This trial is registered at ClinicalTrials.Gov ( NCT03574610 , 2 July 2018.) and Hou
Gefällt mir
Kommentar
Teilen
